Chembio Diagnostics to Report Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022
Chembio Diagnostics, Inc. (CEMI) will release its financial results for Q4 and full year 2021 on March 3, 2022, after market close. A conference call is scheduled for the same day at 4:30 p.m. ET, where management will discuss the results. Interested investors can join the call or access a replay through provided contact details. As a leader in point-of-care diagnostics, Chembio focuses on rapid tests for infectious diseases, including COVID-19, and markets products globally.
- Innovative DPP technology enhancing market applications beyond infectious diseases.
- Strong focus on developing and commercializing rapid diagnostic tests.
- None.
HAUPPAUGE, N.Y., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the fourth quarter and full year 2021 after the close of trading on Thursday, March 3, 2022.
The company’s management team will host a corresponding conference call beginning at 4:30 p.m. Eastern Time on March 3, 2022. Investors interested in listening to the conference call may do so by dialing 888-506-0062 from the US or 973-528-0011 from outside the US and providing Entry Code: 516973 or by accessing www.chembio.com/investors/calendar-of-events/. A replay of the call will be available by dialing 877-481-4010 from the US or 919-882-2331 from outside the US using passcode 44503 or by accessing www.chembio.com/investors/calendar-of-events/.
About Chembio Diagnostics
Chembio is a leading diagnostics company focused on developing and commercializing point-of-care tests used for the rapid detection and diagnosis of infectious diseases, including sexually transmitted disease, insect vector and tropical disease, COVID-19 and other viral and bacterial infections, enabling expedited treatment. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.
Investor contact:
| Philip Taylor Gilmartin Group (415) 937-5406 investor@chembio.com |
FAQ
What date will Chembio Diagnostics release its Q4 and full year 2021 financial results?
What time is the conference call for Chembio Diagnostics' financial results?
How can I listen to the Chembio Diagnostics conference call?
What is the focus of Chembio Diagnostics?
Where can I find Chembio Diagnostics' investor information?
